The clinical role of anakinra in the armamentarium against familial Mediterranean fever

References

• Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019 Feb;48(1 Pt 2):e61–e76. doi: 10.1016/j.lpm.2018.08.014
   PubMed Web of Science ®Google Scholar
• Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–483. doi: 10.1038/sj.ejhg.5200658
   PubMed Web of Science ®Google Scholar
• Güngörer V, Yorulmaz A, Arslan Ş. The clinical effect of gene mutations in familial Mediterranean fever disease. Pediatr Int. 2022;64(1):e15052. doi: 10.1111/ped.15052
   PubMed Web of Science ®Google Scholar
• French FMF Consortium T, Bernot A, Clepet C, et al. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. doi: 10.1038/ng0997-25
   PubMed Web of Science ®Google Scholar
• International FMF Consortium T, The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. doi: 10.1016/S0092-8674(00)80539-5
   PubMed Web of Science ®Google Scholar
• Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020;50(SI–2):1591–1610. doi: 10.3906/sag-2008-11
   PubMedGoogle Scholar
• El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant familial Mediterranean fever (FMF). Orphanet J Rare Dis. 2019;14(1):224. doi: 10.1186/s13023-019-1201-7
   PubMed Web of Science ®Google Scholar
• Satiş H, Armağan B, Bodakçi E, et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turk J Med Sci. 2020;50(5):1337–1343. doi: 10.3906/sag-2001-261
   PubMed Web of Science ®Google Scholar
• Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol. 2017;13(5):393–404. doi: 10.1080/1744666X.2017.1313116
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–1919. doi: 10.1056/NEJMoa1706314
   PubMed Web of Science ®Google Scholar
• Ozen S, Ben-Cherit E, Foeldvari I, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020;79(10):1362–1369. doi: 10.1136/annrheumdis-2020-217419
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Lauwerys B, Miettunen P, et al. Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the cluster trial. Clin Exp Rheumatol. 2021;39(5):51–58. doi: 10.55563/clinexprheumatol/e92f7o
   PubMed Web of Science ®Google Scholar
• Ben‐Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine‐resistant familial Mediterranean fever: a randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumat. 2017;69(4):854–862. doi: 10.1002/art.39995
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Hajj-Ali R, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Bio Med Res Int. 2014;2014:1–8. doi: 10.1155/2014/854842
   Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever. Ann internal med. 2012;157(8):533. doi: 10.7326/0003-4819-157-8-201210160-00003
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis & Rheumatism. 2008;58(8):2443–2452. doi: 10.1002/art.23687
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–2425. doi: 10.1056/NEJMoa0810787
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557–567. doi: 10.1002/art.33342
   PubMed Web of Science ®Google Scholar
• Henes JC, Saur S, Kofler DM, et al. Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, double-blind, placebo-controlled phase II study. J Clin Med. 2022;11(18):5360. doi: 10.3390/jcm11185360
   PubMed Web of Science ®Google Scholar
• Giat E, Ben-Zvi I, Lidar M, et al. The preferential use of anakinra in various settings of FMF: a review applied to an updated treatment-related perspective of the disease. Int J Mol Sci. 2022;23(7):3956. doi: 10.3390/ijms23073956
   PubMed Web of Science ®Google Scholar
• Kacar M, Savic S, van der Hilst, JCH, et al. The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever: a systematic review of the literature. JIR. 2020;13:141–149. doi: 10.2147/JIR.S206204
   Google Scholar
• Aschenbrenner DS. New indication for rilonacept. AJN. 2021;121(7):24–25. doi: 10.1097/01.NAJ.0000758488.05149.a6
   Web of Science ®Google Scholar
• Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with still’s disease. Rheumatology. 2019;58(Supplement_6):vi9–vi22. doi: 10.1093/rheumatology/kez350
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. doi: 10.1093/nar/gkx1037
   PubMed Web of Science ®Google Scholar
• Drug information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf
   Google Scholar
• Kim DC, Reitz B, Carmichael DF, et al. Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci. 1995;84(5):575–580. doi: 10.1002/jps.2600840511
   PubMed Web of Science ®Google Scholar
• Yang BB, Gozzi P, Sullivan JT. Pharmacokinetics of Anakinra in subjects of heavier vs. Clinical Translational Sci. 2019;12(4):371–378. doi: 10.1111/cts.12622
   PubMed Web of Science ®Google Scholar
• Drug information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103950-0_Kineret_Biopharmr.PDF
   Google Scholar
• Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate il-1β production. Proc Natl Acad Sci, USA. 2006;103(26):9982–9987. doi: 10.1073/pnas.0602081103
   PubMed Web of Science ®Google Scholar
• Calligaris L, Marchetti F, Tommasini A, et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167(6):695–696. doi: 10.1007/s00431-007-0547-3
   PubMed Web of Science ®Google Scholar
• Roldan R, Ruiz AM, Miranda MD, et al. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75(4):504–505. doi: 10.1016/j.jbspin.2008.04.001
   PubMed Web of Science ®Google Scholar
• Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dialysis Transplant. 2008;24(2):676–678. doi: 10.1093/ndt/gfn646
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29(2):209–210. doi: 10.1007/s10067-009-1279-8
   PubMed Web of Science ®Google Scholar
• Alpay N, Şumnu A, Çalışkan Y, et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32(10):3277–3279. doi: 10.1007/s00296-010-1474-6
   PubMed Web of Science ®Google Scholar
• Seza Ö, Yelda B, Ayaz Nuray A, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2010;38(3):516–518. doi: 10.3899/jrheum.100718
   PubMed Web of Science ®Google Scholar
• Stankovic Stojanovic K, Delmas Y, Urena Torres P, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dialysis Transplantation. 2011;27(5):1898–1901. doi: 10.1093/ndt/gfr528
   PubMed Web of Science ®Google Scholar
• Estublier C, Stankovic Stojanovic K, Bergerot JF, et al. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. 2013 Dec;80(6):645–9.
   PubMed Web of Science ®Google Scholar
• Mercan R, Turan A, Bitik B, et al. Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Mod Rheumatol. 2014;26(3):458–459. doi: 10.3109/14397595.2014.882221
   PubMed Web of Science ®Google Scholar
• Özçakar ZB, Özdel S, Yılmaz S, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016 Feb;35(2):441–6.
   PubMed Web of Science ®Google Scholar
• Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation. 2014;38(1):27–31. doi: 10.1007/s10753-014-0004-1
   Web of Science ®Google Scholar
• Başaran Ö, Uncu N, Çelikel BA, et al. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015 Jul;25(4):621–4.
   PubMed Web of Science ®Google Scholar
• Eroglu FK, Beşbaş N, Topaloglu R, et al. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35(10):1733–1737. doi: 10.1007/s00296-015-3293-2
   PubMed Web of Science ®Google Scholar
• Kucuksahin O, Yildizgoren MT, Ilgen U, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol. 2017;27(2):350–355. doi: 10.1080/14397595.2016.1194510
   PubMed Web of Science ®Google Scholar
• Abbara S, Georgin-Lavialle S, Stankovic Stojanovic K, et al. Association of hidradenitis suppurativa and familial Mediterranean fever: a case series of 6 patients. Joint Bone Spine. 2017;84(2):159–162. doi: 10.1016/j.jbspin.2016.02.021
   PubMed Web of Science ®Google Scholar
• Laskari K, Boura P, Dalekos GN, et al. Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J Rheumatol. 2016;44(1):102–109. doi: 10.3899/jrheum.160518
   PubMed Web of Science ®Google Scholar
• Ozkan S, Atas B. Canakinumab treatment in four children with colchicine resistant familial Mediterranean fever. J Pak Med Assoc. 2017;67(6):945–947.
   PubMed Web of Science ®Google Scholar
• Nalcacioglu H, Ozkaya O, Genc G, et al. Efficacy of anakinra in a patient with systemic amyloidosis presenting as Amyloidoma. Int J of Rheum Dis. 2018;21(2):552–559. doi: 10.1111/1756-185X.13250
   PubMed Web of Science ®Google Scholar
• Varan Ö, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019;29(2):363–366. doi: 10.1080/14397595.2018.1457469
   PubMed Web of Science ®Google Scholar
• Babaoglu H, Varan O, Kucuk H, et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol. 2019 Feb;38(2):577–581.
   PubMed Web of Science ®Google Scholar
• Yıldırım DG, Bakkaloglu SA, Buyan N. Protracted febrile myalgia as a challenging manifestation of familial Mediterranean fever: case-based review. Rheumatol Int. 2019 Jan;39(1):147–152. doi: 10.1007/s00296-018-4163-5
   PubMed Web of Science ®Google Scholar
• Jesenak M, Hrubiskova K, Kapustova L, et al. Canakinumab as monotherapy for treatment of familial Mediterranean fever – first report in central and Eastern Europe region. BLL. 2018;119(4):198–200. doi: 10.4149/BLL_2018_036
   PubMed Web of Science ®Google Scholar
• Akar S, Cetin P, Kalyoncu U, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care Res. 2018;70(7):1090–1094. doi: 10.1002/acr.23446
   Web of Science ®Google Scholar
• Demir F, Bahadir A, Mungan S, et al. Systemic amyloidosis in a patient with familial Mediterranean fever and Hodgkin Lymphoma: a case report. J Pediatr Hematol Oncol. 2020;42(3):234–237. doi: 10.1097/MPH.0000000000001504
   PubMed Web of Science ®Google Scholar
• Habib G, Levinger U. Medical cannabis in treatment of resistant familial Mediterranean fever. Am J Case Rep. 2019;20:1340–1342. doi: 10.12659/AJCR.917180
   PubMed Web of Science ®Google Scholar
• Sendogan DO, Saritas H, Kumru G, et al. Outcomes of canakinumab treatment in recipients of kidney transplant with familial Mediterranean fever: a case series. Transplant Proc. 2019;51(7):2292–2294. doi: 10.1016/j.transproceed.2019.03.049
   PubMed Web of Science ®Google Scholar
• Çakan M, Karadağ ŞG, Ayaz NA. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases. TurkJpediatr. 2020;62(2):167. doi: 10.24953/turkjped.2020.02.001
   Web of Science ®Google Scholar
• Ayaz NA, Tanatar A, Karadağ ŞG, et al. Comorbidities and phenotype-genotype correlation in children with familial Mediterranean fever. Rheumatol Int. 2021 Jan;41(1):113–120.
   PubMed Web of Science ®Google Scholar
• Şahin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020 Jan 30;60(1):12. doi: 10.1186/s42358-020-0117-1
   PubMedGoogle Scholar
• Kurt T, Aydın F, Nilüfer Tekgöz P, et al. Effect of anti‐interleukin‐1 treatment on quality of life in children with colchicine‐resistant familial Mediterranean fever: a single‐center experience. Int J of Rheum Dis. 2020;23(7):977–981. doi: 10.1111/1756-185X.13891
   PubMed Web of Science ®Google Scholar
• Ozdogan H, Ugurlu S, Uygunoglu U, et al. The efficacy of anti- il-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. Multi Sclerosis Relat Disord. 2020;45:102332. doi: 10.1016/j.msard.2020.102332
   PubMed Web of Science ®Google Scholar
• Talerico R, Cardillo C, De Vito F, et al. Mesothelioma in familial Mediterranean fever with colchicine intolerance: a case report and literature review. Front Immunol. 2020;11:11. doi: 10.3389/fimmu.2020.00889
   PubMed Web of Science ®Google Scholar
• Yeter HH, Yetkin N, Akcay O, et al. Late acute cellular rejection after anakinra treatment in a kidney transplant patient, is it a coincidence? Iran J Kidney Dis. 2020 Jul;14(4):318–320.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ergezen B, Egeli BH, et al. Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2020 Dec 1;59(12):3892–3899. doi: 10.1093/rheumatology/keaa211
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Ergezen B, Egeli BH, et al. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. Rheumatology. 2020;60(5):2327–2332. doi: 10.1093/rheumatology/keaa596
   Web of Science ®Google Scholar
• Atas N, Eroglu GA, Sodan HN, et al. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol. 2021 Sep;39(5):30–36. Suppl 132. doi: 10.55563/clinexprheumatol/815tdt
   PubMed Web of Science ®Google Scholar
• Druyan A, Giat E, Livneh A, et al. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. Clin Exp Rheumatol. 2021 Sep;39(5):75–79. Suppl 132. doi: 10.55563/clinexprheumatol/rrr9zd
   PubMed Web of Science ®Google Scholar
• Simsek C, Karatas M, Tatar E, et al. The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: a study with histopathologic evidence. Clin Transplant. 2021 Jun;35(6):e14309.
   PubMed Web of Science ®Google Scholar
• LLobet Agulló P, Sanromà-Nogués L, Salguero-Pérez IM, et al. Familial Mediterranean fever in the pediatric population. Allergol Immunopathol (Madr). 2022;50(1):25–30. doi: 10.15586/aei.v50i1.446
   PubMed Web of Science ®Google Scholar
• Marko L, Shemer A, Lidar M, et al. Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients. Rheumatology (Oxford). 2021 Jun 18;60(6):2878–2883. doi: 10.1093/rheumatology/keaa728
   PubMed Web of Science ®Google Scholar
• Egeli BH, Ugurlu S. Familial Mediterranean fever: clinical state of the art. QJM. 2020;115(11):711–718. doi: 10.1093/qjmed/hcaa291
   Web of Science ®Google Scholar
• Cebeci SO, Yildiz M, Gunalp A, et al. The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever. Rheumatol Int. 2023; [cited 2023 Oct 10]. doi: 10.1007/s00296-023-05351-0
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196:AID-ART15>3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Malcova H, Strizova Z, Milota T, et al. IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives. Front Immunol. 2021 Feb 1;11:619257.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006;355(6):581–592. doi: 10.1056/NEJMoa055137
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of muckle-wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15(3):R64. doi: 10.1186/ar4237
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory muckle-wells syndrome. Arthritis Rheum. 2011;63(3):840–849. doi: 10.1002/art.30149
   PubMed Web of Science ®Google Scholar
• Kullenberg T, Löfqvist M, Leinonen M, et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016;55(8):1499–1506. doi: 10.1093/rheumatology/kew208
   PubMed Web of Science ®Google Scholar
• Varan O, Kucuk H, Babaoglu H, et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clin Rheumatol. 2018;38(4):1125–1130. doi: 10.1007/s10067-018-4384-8
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Akcin R, Ayla AY, et al. Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors. Rheumatology (Oxford). 2022;61(SI2):SI194–SI196. doi: 10.1093/rheumatology/keac123
   PubMed Web of Science ®Google Scholar
• Massaro MG, Caldarelli M, Franza L, et al. Current evidence on vaccinations in pediatric and adult patients with systemic autoinflammatory diseases. Vaccines (Basel). 2023;11(1):151. doi: 10.3390/vaccines11010151
   PubMed Web of Science ®Google Scholar
• Güven SC, Karakaş Ö, Atalar E, et al. A single-center COVID-19 vaccine experience with CoronaVac and BNT162b2 in familial Mediterranean fever patients. Int J Rheum Dis. 2022;25(7):787–794. doi: 10.1111/1756-185X.14349
   PubMed Web of Science ®Google Scholar
• Tomokawa T, Koga T, Endo Y, et al. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: a single-centre observational study. Mod Rheumatol. 2022;32(4):797–802. doi: 10.1093/mr/roab048
   PubMed Web of Science ®Google Scholar
• Rigante D, Ansuini V, Caldarelli M, et al. Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst. 2006;22(4):334–337. doi: 10.1007/s00381-006-1280-3
   PubMed Web of Science ®Google Scholar
• Marchica C, Zawawi F, Basodan D, et al. Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of muckle-wells syndrome treated with Anakinra: a case report and review of the literature. J Otolaryngol Head Neck Surg. 2018;47(1):9. doi: 10.1186/s40463-018-0256-0
   PubMedGoogle Scholar